Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medical Imaging
Published in: BMC Medical Imaging 1/2018

Open Access 01-12-2018 | Research article

Prognostic value of metabolic tumor volume of pretreatment 18F-FAMT PET/CT in non-small cell lung Cancer

Authors: Soma Kumasaka, Takahito Nakajima, Yukiko Arisaka, Azusa Tokue, Arifudin Achmad, Yasuhiro Fukushima, Kimihiro Shimizu, Kyoichi Kaira, Tetsuya Higuchi, Yoshito Tsushima

Published in: BMC Medical Imaging | Issue 1/2018

Login to get access

Abstract

Background

This study aimed to determine the prognostic value of positron emission tomography (PET) metabolic parameters—namely metabolic tumor volume (MTV), total lesion glycolysis (TLG), and total lesion retention (TLR)—on fluorine-18 (18F) fluorodeoxyglucose (FDG) and L- [3-18F]-α-methyltyrosine (18F-FAMT) PET/CT in patients with non-small-cell lung cancer (NSCLC).

Methods

The study group comprised 112 NSCLC patients who underwent 18F-FDG and 18F-FAMT PET/CT prior to any therapy. The MTV, TLG, TLR, and maximum standardized uptake value (SUVmax) of the primary tumors were determined. Automatic MTV measurement was performed using PET volume computer assisted reading software. (GE Healthcare). Cox proportional hazards models were built to assess the prognostic value of MTV, TLG (for 18F-FDG), TLR (for 18F-FAMT), SUVmax, T stage, N stage, M stage, clinical stage, age, sex, tumor histological subtype, and treatment method (surgery or other therapy) on overall survival (OS).

Results

Higher TNM, higher clinical stage, inoperable status, and higher values for all PET parameters (both 18F-FAMT and 18F-FDG PET) were significantly associated (P < 0.05) with shorter OS. Multivariate analysis revealed that a higher MTV of 18F-FAMT (hazard ratio [HR]: 2.88, CI: 1.63–5.09, P < 0.01) and advanced clinical stage (HR: 5.36, CI: 1.88–15.34, P < 0.01) were significant predictors of shorter OS.

Conclusions

MTV of 18F-FAMT is of prognostic value for OS in NSCLC cases and can help guide decision-making during patient management.
Literature
1.
Navada S, Lai P, Schwartz A, Kalemkerian G. Temporal trends in small cell lung cancer: analysis of the National Surveillance, Epidemiology, and End Results Database. J Clin Oncol. 2006;24(18):384s (abstract 7082).
2.
Woodard GA, Jones KD, Jablons DM. Lung Cancer staging and prognosis. Cancer Treat Res. 2016;170:47–75.CrossRef
3.
Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallières E, Groome P, et al. The IASLC lung Cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung Cancer. J Thorac Oncol. 2017;12:1109–21.CrossRef
4.
van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest. 2000;117:374–9.CrossRef
5.
Hicks RJ, Kalff V, MacManus MP, Ware RE, Hogg A, McKenzie AF, et al. (18) F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596–604.PubMed
6.
Hicks RJ, Kalff V, MacManus MP, Ware RE, McKenzie AF, Matthews JP, et al. The utility of (18) F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med. 2001;42:1605–13.PubMed
7.
Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer. 2002;35:179–87.CrossRef
8.
Hoekstra CJ, Stroobants SG, Hoekstra OS, Vansteenkiste J, Biesma B, Schramel FJ, et al. The value of [18F] fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer. 2003;39:151–7.CrossRef
9.
Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, De Leyn PR, De Wever W, Verbeken EK, et al. The impact of (18) F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non–small cell lung cancer. Radiother Oncol. 2000;55:317–24.CrossRef
10.
Nestle U, Kremp S, Grosu AL. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol. 2006;81:209–25.CrossRef
11.
Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European lung Cancer working Party for the International Association for the study of lung Cancer staging project. J Thorac Oncol. 2010;5:612–9.CrossRef
12.
Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, et al. Prognostic value of volumetric parameters of (18) F-FDG PET in non-small cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42:241–51.CrossRef
13.
Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53:1506–13.CrossRef
14.
Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park NH, et al. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol. 2011;120:270–4.CrossRef
15.
Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, et al. Volume-based assessment by (18) F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:50–8.CrossRef
16.
Lemarignier C, Di Fiore F, Marre C, Hapdey S, Modzelewski R, Gouel P, et al. Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:2008–16.CrossRef
17.
Tomiyoshi K, Amed K, Muhammad S, Higuchi T, Inoue T, Endo K, et al. Synthesis of new fluorine-18 labeled amino acid radiopharmaceutical: L-F-α-methyl tyrosine using separation and purification system. Nucl Med Commun. 1997;18:169–75.CrossRef
18.
Wiriyasermkul P, Nagamori S, Tominaga H, Oriuchi N, Kaira K, Nakao H, et al. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med. 2012;53:1253–61.CrossRef
19.
Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, et al. Fluorine-18-α-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathological study. Clin Cancer Res. 2007;13:6369–78.CrossRef
20.
Wei L, Tominaga H, Ohgaki R, Wiriyasermkul P, Hagiwara K, Okuda S, et al. Specific transport of 3-fluoro-l-α-methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging. Cancer Sci. 2016;107:347–52.CrossRef
21.
Kim M, Achmad A, Higuchi T, Arisaka Y, Yokoo H, Yokoo S, et al. Effects of intratumoral inflammatory process on 18F-FDG uptake: pathologic and comparative study with 18F-fluoro-α-methyltyrosine PET/CT in oral squamous cell carcinoma. J Nucl Med. 2015;56:16–21.CrossRef
22.
Morita M, Higuchi T, Achmad A, Tokue A, Arisaka Y, Tsushima Y. Complementary roles of tumour specific PET tracer 18F-FAMT to 18F-FDG PET/CT for the assessment of bone metastasis. Eur J Nucl Med Mol Imaging. 2013;40:1672–81.CrossRef
23.
Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, et al. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med. 2009;50:1770–6.CrossRef
24.
Kaira K, Oriuchi N, Yanagitani N, Sunaga N, Ishizuka T, Mori M, et al. Assessment of therapy response in lung cancer with 18F-α-methyl tyrosine PET. AJR Am J Roentgenol. 2010;195:1204–11.CrossRef
25.
Kaira K, Oriuchi N, Shimizu K, Imai H, Tominaga H, Yanagitani N, et al. Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-α-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nucl Med Biol. 2010;37:911–6.CrossRef
26.
Davison J, Mercier G, Russo G, Subramaniam RM. PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. AJR Am J Roentgenol. 2013;200:635–40.CrossRef
27.
Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264:559–66.CrossRef
28.
Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:27–38.CrossRef
29.
Chung HW, Lee KY, Kim HJ, Kim WS, So Y. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. J Cancer Res Clin Oncol. 2014;140:89–98.CrossRef
30.
Bazan JG, Duan F, Snyder BS, Horng D, Graves EE, Siegel BA, et al. Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235. Eur J Nucl Med Mol Imaging. 2017;44:17–24.CrossRef
31.
Carlier T, Bailly C. State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET. Front Med (Lausanne). 2015;2:18.PubMedPubMedCentral
32.
Moon SH, Hyun SH, Choi JY. Prognostic significance of volume-based PET parameters in cancer patients. Korean J Radiol. 2013;14:1–12.CrossRef
33.
van Baardwijk A, Bosmans G, Boersma L, Buijsen J, Wanders S, Hochstenbag M, et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys. 2007;68:771–8.CrossRef
34.
Kim M, Higuchi T, Arisaka Y, Achmad A, Tokue A, Tominaga H, et al. Clinical significance of 18F-α-methyl tyrosine PET/CT for the detection of bone marrow invasion in patients with oral squamous cell carcinoma: comparison with 18F-FDG PET/CT and MRI. Ann Nucl Med. 2013;27:423–30.CrossRef
35.
Suzuki S, Kaira K, Ohshima Y, Ishioka NS, Sohda M, Yokobori T, et al. Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer. Br J Cancer. 2014;110:1985–91.CrossRef
Metadata
Title
Prognostic value of metabolic tumor volume of pretreatment 18F-FAMT PET/CT in non-small cell lung Cancer
Authors
Soma Kumasaka
Takahito Nakajima
Yukiko Arisaka
Azusa Tokue
Arifudin Achmad
Yasuhiro Fukushima
Kimihiro Shimizu
Kyoichi Kaira
Tetsuya Higuchi
Yoshito Tsushima
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Medical Imaging / Issue 1/2018
Electronic ISSN: 1471-2342
DOI
https://doi.org/10.1186/s12880-018-0292-2

Other articles of this Issue 1/2018

BMC Medical Imaging 1/2018 Go to the issue

Research article

Evaluation of quantitative parameters of dynamic contrast-enhanced magnetic resonance imaging in qualitative diagnosis of hepatic masses

Research article

An automated algorithm for the detection of cortical interruptions and its underlying loss of trabecular bone; a reproducibility study

Research article

MRI assessment of aortic flow in patients with pulmonary arterial hypertension in response to exercise

Research article

Value of flaccid penile ultrasound in screening for arteriogenic impotence: a preliminary prospective study

Research article

Gadoxetic acid-enhanced magnetic resonance imaging significantly influences the clinical course in patients with colorectal liver metastases

Research article

2D/3D CMR tissue tracking versus CMR tagging in the assessment of spontaneous T2DM rhesus monkeys with isolated diastolic dysfunction